Infusion Pumps – Market Insights – Europe

The European infusion pump demand will be underpinned by aging populations and rising chronic disease, while accelerating adoption of closed-loop, EHR-integrated smart pumps and growing demand of non-hospital settings will stimulate the demand for disposable and electronic ambulatory pumps. Premium, physician-preferred closed-loop insulin systems will support, but limited reimbursement for type 2 diabetes and EU Debt Rule fiscal constraints in Italy and Spain will moderate smart pump uptake.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for infusion pumps in Europe from 2019 through 2034.

The increasing popularity of non-hospital set-ups and ambulatory care will drive the sales across few segments.

How are shifting epidemiological patterns—rise in chronic diseases and aging populations—complementing the growth of non-hospital care settings like ambulatory centers in Europe?

How will France’s reimbursement extension for ambulatory infusion pumps under LPPR make the market more attractive for competitors?

How could the EU’s new debt rules influence the shift toward ambulatory care by shaping public investment priorities in healthcare infrastructure?

The shift toward the utilization of advanced products with smart programming will boost market growth.

Which market will be impacted by the adoption of these advanced products?

Which competitors have innovative devices and are likely to capitalize on this trend?

Adoption of closed loop smart pumps with EHR integration will drive market growth.

How has the launch of hybrid closed-loop insulin delivery systems impacted the market?

How fast does share migrate to vendors offering endtoend integration (pump, EHR, drug library, analytics) versus point solutions?

What are the latest innovations in the insulin patch pump market?